Some new Yescarta data | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

GILD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11884 of 11894  at  6/11/2019 9:23:07 AM  by

captsolo


 In response to msg 11883 by  mymorningsong
view thread

Re: Some new Yescarta data

If JUNO's Liso-Cel is approved it will be 12 months from now. I don't think it comes close to matching up with ZUMA 1 (or other ZUMA trials with CR as high as 80%), and FDA surely knows the same, so I say Liso-Cel isn't worthy of approval - especially since the CR is lower than ZUMA 1 (over 250 patients including real life).

Why would a doctor / hospital ask for it over Yescarta? CR rate of 46% is NOT better than Yescarta in real world.

JUNO missed the boat IMO.

Kymriah's manufacturing issues got so bad that FDA would not let them sell it commercially - but could only give it away.

GILD on the other hand has had zero manufacturing issues with their CAR T.

Yescarta will have 4 years of no deaths by the time Liso-Cel (just old JCAR15?) https://www.fiercebiotech.com/r-d/juno-ditches-lead-car-t-program-following-patient-deaths


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 182
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
11885 Re: Some new Yescarta data mymorningsong 1 6/11/2019 10:16:57 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...